Drug intelligence / Profile preview

AB-SA01

Development stage: Phase 1
Lead developer: Armata Pharmaceuticals
Modality: Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Intravenous, Topical, Intranasal

Overview

AB-SA01 is a clinical-stage, natural bacteriophage therapeutic candidate being developed by Armata Pharmaceuticals. It was originally developed by AmpliPhi Biosciences before its merger with C3J Therapeutics to form Armata. AB-SA01 targets serious and life-threatening infections caused by the bacterium *Staphylococcus aureus*, including antibiotic-resistant strains. The therapy consists of a cocktail of naturally occurring bacteriophages that specifically target and lyse *S. aureus*. It has been evaluated in a Phase 1 clinical trial for topical safety and has been provided to patients with severe infections under an expanded access program.

Other names: staphylococcus aureus phage

Targets

bacterial dsDNA (Bacterial double-stranded DNA)

Beyond the preview

Go deeper on AB-SA01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AB-SA01.

Explore the full profile